Try our Advanced Search for more refined results
Life Sciences - September, 2013
235 articles
- MLB Drug Clinic May Face Fla. Criminal Suit
- Bristol-Myers, Citigroup Hit In $27M NJ Superfund Suit
- RyMed Prevails In Rival's Catheter Connector Patent Suit
- Safeway Rehashed Doryx Antitrust Claims In New Suit: Judge
- NIH Cleared To Fund $128M Anthrax Research Lab In Boston
- Ex-Adviser Cops To Insider Trading Tied To $11B Pharma Deal
- FDA To Halt Inspections, Dial Back Enforcement In Shutdown
- Clinton Group Buys More Nutrisystem, Asks Higher Dividend
- Paxil Birth Defect Suit Sent Back To Pa. State Court
- Senate Nixes House Spending Resolution As Shutdown Looms
- Biomet Sued Over $3M Scheme To Steal Stryker Sales Reps
- Aspen Puts Up $1B For Pair Of GSK Blood Thinners
- ACLU Slams DEA In Prescription Records Privacy Fight
- Plavix Hemorrhage Complaints Growing In NY State Court
- Deals Rumor Mill: Lloyds, Glencore, Twitter
- NJ Court Reinstates Bristol-Myers Wrongful Death Suits
- Pa. Judge Denies GSK's Attempts To Nix Thalidomide Suits
- GSK Can't Shake Antitrust Claims Of Drug Discount Abuse
- Diabetes Supplement Co.'s Expert 'Incoherent,' Judge Says
- FDA OKs Boxed Death Risk Alert For Pfizer Antibiotic
- Medtronic Nets $10M Settlement To End Insulin Pump Fight
- 5 Takeaways From FDA's Unique Device ID Rule
- Md. Negligence Doctrine Gives Takeda Win In Actos Suit
- FTC OKs Actavis' $8B Warner Chilcott Buy With Conditions
- Nexium Case Begins To Define Contours Of Actavis Decision
- FTC Demands Drug Divestment For $1.9B Mylan, Agila Merger
- Fed. Circ. Nixes Dr. Reddy's Patent Win On Generic Lunesta
- Siemens Settles Class Action Over HearUSA Stock Price
- Landauer Pursues Ch. 11 Plan After Stalking Horse Debt Buy
- House, Senate Panels Agree On Compounder Oversight Bill
- FDA Says Drug Companies May Be Abusing Petition Process
- Obviousness Of Claims: Common Sense Alone Is Not Enough
- How To Respond When FDA Knocks
- Rakoff Scolds Lupin For 'Fecklessness' In Antara Patent Row
- Nobel Fights $4M Attys' Fee Bid In Dental Implant Suit
- FDA Rips Unsanitary Practices Of India Drug Co. In Mylan Buy
- Par, Purdue Settle IP Claims In OxyContin Antitrust MDL
- Drug Comparison Suits May Drive Shift In Pharma Ads
- IP Group Asks High Court To Keep Burden On Licensees
- How To Avoid Pitfalls Of Hiring Gov't Officials' Relatives
- Pfizer Unit Wins $60M HHS Contract For Nerve Gas Treatment
- Skadden Reps Stryker In $1.65B Surgical Robotics Co. Buyout
- EU Parliament Committee OKs Special Medical Device Checks
- Hazy FDA Rules Cloud Medical Food's Future
- AngioDynamics Renews Bid For Biolitec Sanctions In IP Row
- 9th Circ. Affirms Remand Of Painkiller Suit To State Court
- 7 Takeaways From FDA's Mobile Medical Apps Guidance
- Cephalon Mustn't Talk IP At Pay-For-Delay Trial, FTC Says
- Hungarian Drugmaker Egis Draws $483M Offer From Servier
- DePuy Hits 2 Ex-Employees With Breach Of Contract Suit
- BigLaw IP Partner ID'd As Alleged Drunk Tipster In SEC Case
- GSK's Data Woes A Warning For Others, NY Judge Says
- Forest Sues Mylan, Others To Block Generic Savella
- Rite-Aid, Wal-Mart Can't Shake Glucosamine False Ad Suit
- Mensing Doesn't Nix Generic-Fosamax Claims, 3rd Circ. Told
- Applying Double-Patenting Safe Harbor After St. Jude
- A New Era Of Post-Plea Compliance Obligations
- And Now A Word From The Panel ...
- Pay-For-Delay Ruling May Be Boon For Attys, Experts Say
- Murky HIPAA Marketing Guidance Creates Costs Headache
- Vista Equity Buys Medical Software Co. For $644M
- Novartis Challenges $1.3M Verdict In Zometa Jaw Injury Suit
- 1st Hip Implant MDL Bellwether Against J&J Delayed Again
- Oxycontin Patents Not Infringed, Drug Cos. Say At Trial
- Biomaterial Co. MiMedx Accused Of Defrauding Investors
- Risperdal Marketing Appeals Dropped In Pa. Appeals Court
- GE, Lilly Rip Proposed Biz Method Patent Review Expansion
- A Snapshot Of The Anti-Bribery Enforcement Landscape
- FDA Overhauls Painkiller Patch Labels After Child Deaths
- FDA Finalizes Long-Sought Mobile Medical Apps Guidance
- Myriad GC Soft-Pedals Importance Of High Court IP Ruling
- AbbVie Will Pay Up To $840M For Ablynx Licensing Deal
- Nordion Settles $90M Mad Cow Contamination Suit
- Amgen Scores Sweet BofA Debt Terms In $10.4B Onyx Deal
- 2nd Circ. Won't Rehear Schemer's $10M Morgan Stanley Case
- HIPAA Revisions Arrive Amid Lingering Confusion
- Cancer Drug Firm Ducks Shareholder Suit Over $26M Offering
- Biosimilars Don't Deserve Unique Name, Group Tells FDA
- Tipsy Lawyer Disclosed Secret $3.6B Pfizer Deal, SEC Says
- HHS Clarifies Pay Rules For 3rd-Party Refill Reminder Cos.
- FDA Issues Final ID Rule For Medical Devices
- Jury Orders Becton To Pay $114M In Syringe Antitrust Case
- Nautilus Takes Heart Rate Monitor IP Case To High Court
- How Lawyers Can Effectively Build A Reputation Online
- Post-Acute Sector Deal Activity Increases In 2013
- LOM Medical Shareholders Lose Bid For New Board Election
- Sanofi Settles Obesity Drug Class Action For $40M
- 4 Ways To Make Sure Comments On Agency Rules Count
- Investor Says Chiesi 'Coerced' Cornerstone Into $255M Buyout
- Fla. Medical Device Co. Accused Of Misleading Investors
- The Novel And Emerging Scholastic Privilege
- Burden Of Proof On Patent Licensees, High Court Told
- Mich. AG Floats Compounding Pharmacy Reform Bill
- Univ. Of Pittsburgh Fires Up Cell-Incubation Patent Suit
- Deals Rumor Mill: Roche, JPMorgan, Goldman Sachs
- Amgen's $10B Onyx Deal Gets Antitrust Approval
- Sanofi Accused Of Shorting Staff For Sales Of Cancer Drug
- Medtronic Breach Claims Not Time-Barred, DuPont Says
- Ex-Banker Admits To Hiding Money In $1.7B Olympus Fraud
- 3rd Circ. Adopts Unheard-Of Consumer Class Action Hurdle
- How In-House Counsel Avoid Breaking Bad As Biz Advisers
- High Court Urged Not To Take Novo Foreign Liability Case
- House Small-Business Panel OKs GOP Regulatory Reform Bill
- GSK Asks 9th Circ. For New Trial After Gay Juror Booted
- Drug Repackager To Halt Practices After FDA Mislabeling Suit
- Masimo Faces Sanctions Bid Over Discovery In FCA Fight
- J&J Says $175M Shareholder Suit Requires Board Approval
- Rainmaker Q&A: DLA Piper's Stasia Kelly
- Abbott Moves To Toss Humira Suit Following Court's Sidestep
- A Powerful Tool To Effectively Fight Fraud
- Travelers Fights Cephalon Bid To Nix $22M Marketing Suit
- 8th Circ. Urged To Revive CMS Bidding Program Dispute
- Boston Scientific Settles Coronary-Stent Patent Disputes
- Edwards' Invalidity Claims Tossed In Nerve-Tech Patent Row
- Supreme Court Asked To Weigh Hospira Drug-Shortage Suit
- Mass. PE Firm Takes Majority Stake In Pharmacy Software Co.
- Dukes Prevents Class Cert. In Nexium MDL, AstraZeneca Says
- Deals Rumor Mill: Repsol, Lloyds, Total
- Novartis Beats Subpoenas In Jaw-Injuries Drug Suit
- Baxter Wins Bid To Compel FDA Testimony In Plasma MDL
- Warner Chilcott Sued Over Loestrin Pay-For-Delay Scheme
- Resveratrol Supplement Maker Sued Over 'Organic' Claims
- FDA Blocks Imports From Another Ranbaxy Drug Plant
- Boston Scientific Hit By Inventor's $570M Contract Suit
- Investors Sue Fertility Treatment Co. Following FDA Letter
- 6th Circ. Asked To Revive Cleanup Suit Against GSK, Coke
- CORRECTED: FTC's Brill Vows To Fight Against Pay-For-Delay
- Epstein Becker Nabs Ober Kaler Health Care Pro
- Morgan Lewis Guides Chiesi In $255M Cornerstone Takeover
- Navigating Conflicts When Serving 3rd-Party Subpoenas
- Arthrex Asks High Court To Nix $85M Suture Patent Verdict
- Pfizer Wants High Court To Review 1st Circ. RICO Rulings
- House Bill Would Revamp Compounding Pharmacy Oversight
- Pfizer Urges 3rd Circ. To Uphold Alzheimer Drug Ruling
- AstraZeneca Can't Block Generic Nexium During Appeal
- Wal-Mart Charged Premium For Migraine Meds, Suit Says
- Whistleblower Wants Cephalon FCA Suit Moved To Pa.
- Covidien IV Disinfectant Caps Targeted In Patent Suit
- Merck, BMS Target Aurobindo Over Generic HIV Drug
- Chinese Authorities Eye Bayer Amid Pharma Bribery Probe
- 10 Reasons You Should Value Your Chief Compliance Officer
- An Update On Resale Price Maintenance in China
- Eli Lilly Levels $500M Attack On Canadian Patent Law
- AstraZeneca Can't Dodge Nexium Antitrust Claims
- FTC Wants Access To Boehringer Docs In Pay-For-Delay Probe
- Landauer, Creditors Settle Differences Over Ch. 11 Sale
- Fed. Circ. Nixes Pronova's Patent Win Against Teva, Par
- Spotlight On Spoliation
- Ensure Drink Maker Can't Dodge False Ad Suit
- Fed. Circ. Clears Medtronic In Gore Stent Patent Case
- $886M Otsuka Buyout Cheats Astex Investors, Suit Says
- HHS Will Launch Guidance On HIPAA Health Privacy Rules
- Pharmacists' Groups Sue Maine Over Drug Importation Law
- FDA Floats Drug Assessment Guidelines For Pharma Cos.
- Landauer Slams Creditors' Objections To Ch. 11 Sale Process
- BioSante Freed From 2 Investor Suits Over Libido Drug
- St. Jude Patent Not Shielded By Safe Harbor, Fed. Circ. Says
- Docs In Cephalon Pay-For-Delay Row Protected, Judge Says
- Quest Diagnostics Ducks ERISA Suit Over Severance Benefits
- Herbalife Exploits Hispanics, Latina Group Tells FTC
- Boiron Faces New False Ad Suit Over Homeopathic Flu Drug
- Allergan Asks Fed. Circ. For Block On Generic Zymaxid
- FDA Guidance Smoothes Advair Generic Approval Process
- How Courts Consider Patent Injunction's Impact On Public
- Travelers Again Told To Surrender Docs In Heparin Suit
- 8th Circ. Urged To Reopen Stryker FCA Pain Pump Suit
- In-House Counsel To Firms: Do More With Less
- Pfizer Denied Interlocutory Appeal In Pay-For-Delay MDL
- EU Approves Hospira's Inflectra In Biosimilars Milestone
- Medicare Could Collect Billions Via Drug Co. Rebates: OIG
- Bristol-Myers Squibb GC Notches Corporate Practice Award
- Patent Infringement Can Be Anti-Competitive, Judge Rules
- 5 Tips For Fattening Firm Wallets In Lean Times
- Okla. Appeals Court Backs $15M Award In Botox Injury Case
- FDA Overhauls Opioid Painkiller Labels, Urging Careful Use
- In NJ, 'Watchdog' Employees Can Get Protection Too
- Agilent Probes China Misconduct, Possible FCPA Violations
- Conclusory Allegations Won't Cut It Under FCA
- Attys Ask Fed. Circ. For More Fees In TheraSense Suit
- Sandoz Agrees To Shelve Plans For Generic Zetia
- Biogen Pays $100M In New Isis Pharma Alliance
- Courts Rein In FCA Suits Over Medicare Billing Mistakes
- The 4 Firms In-House Counsel Fear The Most
- NJ's Top Gov't Fraud Prosecutor Returns To Lowenstein
- UCB Beats Apotex's IP Suit Over Drugmaking Process
- GSK, Teva Say Lamictal Deal Doesn't Break Antitrust Law
- Japan's Suntory Spends $2B On Glaxo UK Drink Brands
- Why Growth In Nanotechnology Matters To Insurers
- Synbias Co-Owns Cancer Drug IP, Can't Be Sued, Judge Rules
- US Investigates GSK Following Chinese Bribery Claims
- Avanir Settles With Wockhart Over Planned Nuedexta Generic
- Health Privacy Rules Ruining Business, Contractor Says
- 3 Must-Watch Issues For Drug Cos. In 2013's Final Stretch
- Class Cert. Denied In Purdue Pharma Spam Fax Suit
- Deals Rumor Mill: Verizon, Johnson & Johnson, KKR
- Rainmaker Q&A: Faegre's Morgan Burns
- Jury Clears Breast Implant Maker Of Trade Secrets Claims
- FDA Staff Says GSK Is Missing Data On Pulmonary Drug
- China's 1st Step Toward More Participation In Rulemaking
- NJ Appeals Court Affirms Merck Win In Sewer Rights Case
- AstraZeneca Asks Fed. Circ. To Reopen Nexium Patent Suit
- FDA Vows To Speed Up Some Medical Device Guidance
- Warner To Pay Mylan $12M In Damages After Doryx IP Row
- Australian Antitrust Agency OKs Baxter's $4B Gambro Buy
- Deals Rumor Mill: Suntory, America Movil, TDR Capital
- Cash Offsets Count As Monetary Gain, 3rd Circ. Says
- Genentech Sues Rivals Over Generic Anti-Viral Drug Plans
- Funding Gap For Life Science Cos. Is Still A Problem
- Calif. Legislature Sends Biosimilar Drug Bill To Gov.
- 'Watchdog Employees' Can Claim Retaliatory Firing: NJ Court
- Doc Can't Block Bausch & Lomb's Slogan Use, Judge Says
- FDA Urged To Block Unapproved Post-Surgery Injections
- Otsuka Reaches $900M Deal For Oncology Drug Co. Astex
- Texas Inks $5M Deal With Drug Co. Over Medicaid Drug Prices
- Teva Pushes For Rehearing In Pa. Reglan Appeal
- Hospira Recalls IV Solution Following Hair Scare
- 3M Ducks Contract Suit Over $854M Pharma Unit Sale
- GenVec Ditches Liquidation Plan For Novartis Partnership
- Actavis Ducks Endo's Opana False Ad Suit In NJ
- PhRMA Backs Increased FDA Drug Import Controls
- BioMerieux Inks $450M Deal For Molecular Biology Co.
- Bartlett Doesn't Apply To Zometa Injury Suit, Judge Says
- Nutter McClennen Lands Ex-Fresenius Associate GC In Boston
- Can Antitrust Laws Prevent Abuse Of FDA Risk Programs?
- Weil Steers Bard In $262M Rochester Medical Buy
- Olympus Charged In UK Over $1.7B Accounting Fraud
- GSK China Allegedly Had A Hand In Bribery Scheme
- Doc's Errors Tainted Clinical Trial Data, FDA Says
- Deals Rumor Mill: Glencore, Warburg Pincus, Apax
- Lundbeck Fights $125M Pay-For-Delay Fine In EU
- Gilead Says New Hepatitis Drug Does Not Infringe Merck IP
- Takeda Again Sues Par Over Generic Gout Drug
- Bayer Can't Sink Whistleblower's Drug Kickback Claims
- Keeping Secrets Secret: A Primer On Economic Espionage
- A Broken Promise For Pharma Manufacturers